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Abstract
 
Podocalyxin is a CD34-related sialomucin that is expressed at high levels by podocytes, and
also by mesothelial cells, vascular endothelia, platelets, and hematopoietic stem cells. To eluci-
date the function of podocalyxin, we generated podocalyxin-deficient (
 
podxl
 
 
 
/
 
 
 
) mice by ho-
mologous recombination. Null mice exhibit profound defects in kidney development and die
within 24 hours of birth with anuric renal failure. Although podocytes are present in the glo-
meruli of the 
 
podxl
 
 
 
/
 
  
 
mice, they fail to form foot processes and slit diaphragms and instead ex-
hibit cell–cell junctional complexes (tight and adherens junctions). The corresponding reduc-
tion in permeable, glomerular filtration surface area presumably leads to the observed block in
urine production. In addition, 
 
podxl
 
 
 
/
 
 
 
 mice frequently display herniation of the gut (ompha-
locele), suggesting that podocalyxin may be required for retraction of the gut from the umbili-
cal cord during development. Hematopoietic and vascular endothelial cells develop normally in
the podocalyxin-deficient mice, possibly through functional compensation by other sialomucins
(such as CD34). Our results provide the first example of an essential role for a sialomucin in de-
velopment and suggest that defects in podocalyxin could play a role in podocyte dysfunction in
renal failure and omphalocele in humans.
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endothelium
 
Introduction
 
Podocalyxin (also called podocalyxin-like protein 1
[PCLP-1], Myb-Ets–transformed progenitor (MEP)21,
and thrombomucin) is a heavily sialyated and sulfated
membrane protein expressed on the apical surface of
glomerular epithelial cells or podocytes and on vascular
endothelia (1, 2). Although first described as a marker of
podocytes and vasculature, podocalyxin expression has
also been detected on mesothelial cells lining the coelomic
cavity, platelets, and hematopoietic precursors cells (3–7).
Recent experiments in avians and mice have shown that
podocalyxin also marks the earliest detectable hematopoi-
etic progenitors during development (5) as well as bipo-
tent progenitors of blood cells and vascular endothelia
called hemangioblasts (7).
Biochemical and sequence analysis have shown that
podocalyxin is a 150–165-kD transmembrane protein
composed of a mucin domain, a disulfide-bonded globular
domain, a transmembrane region, and a highly charged cy-
toplasmic tail with potential phosphorylation sites for pro-
tein kinase C and casein kinase II (Fig 1). Structurally, it
belongs to a large family of highly sulfated cell surface sialo-
mucins of poorly understood functions. The amino acid se-
quence, protein structure, and genomic organization of
podocalyxin suggest it is most closely related to two other
molecules, CD34 and endoglycan (Fig. 1; references 5 and
8). CD34 is the prototypic member of this family and has
been widely used in human and mouse as marker of he-
matopoietic progenitor cells and vascular endothelia (for a
review, see reference 9). On high endothelial venules
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(HEVs)
 
*
 
 CD34 (1) and podocalyxin (1) have been shown
to act as an adhesive ligand for L-selectin expressed by leu-
kocytes (10). This interaction requires HEV-specific glyco-
sylation of CD34, and similar modifications have not been
observed on the majority of vascular endothelial cells (ECs)
or hematopoietic cells. Thus, it is remarkable that despite
extensive use as a marker (
 
 
 
7,000 CD34-related publica-
tions), the functional role of CD34 on hematopoietic cells
and most vascular cells remains obscure. Mice lacking
CD34 develop normally (11, 12) although very subtle de-
fects in hematopoietic maturation and function can be de-
tected in in vitro assays or in in vivo assays of allergic re-
sponses. Endoglycan is the newest member of this gene
family and has a broader distribution as it is expressed by
hematopoietic progenitors and some mature blood cells,
vascular endothelia, smooth muscle, and a subset of neu-
ronal cells (13). Its function, too, is unknown.
Podocalyxin has been studied most extensively as a
marker of kidney podocytes, which are epithelial cells that
form a meshwork supporting the glomerular capillaries.
The cellular architecture of podocytes can be described in
three segments: the cell body, the major processes (MPs),
and the foot processes (FPs; reference 14). The cell body
and the MPs of the podocyte lie in the urinary space and
are attached to the glomerular basement membrane (GBM)
via the FPs. During glomerular development podocalyxin
is first expressed on the apical surface of podocytes as they
differentiate from epithelial precursors (15). Its expression
then migrates laterally between cells and closely mirrors the
appearance of open intercellular spaces between podocytes
and the migration of occluding junctions down towards the
basal surface of the podocyte. Close to this basal surface
highly interdigitating FPs form and this is coupled to the
modification of intercellular junctions to form slit dia-
phragms (SDs; reference 15). The slit diaphragm is a modi-
fied adherens junction (AJ) that defines the apical and baso-
lateral surfaces of the mature podocyte FPs (16). During
glomerular filtration, plasma is filtered through fenestrae in
Figure 1. Protein structure and genomic
organization of podocalyxin and the CD34
subfamily of sialomucins. (A) Schematic
representation of the structure of murine
CD34, podocalyxin, and endoglycan based
on predicted protein sequences. White
boxes, mucin domains; black boxes, cys-
teine-rich domains; circles, potential NH2-
linked carbohydrates; horizontal bars with
or without arrows, potential O-linked car-
bohydrates; arrows, potential sialic acid mo-
tifs on O-linked carbohydrates; protein
kinase C, TK, and CK2, potential phos-
phorylation sites; DTHL or DTEL, poten-
tial PDZ domain docking sites. (B) Sche-
matic showing the genomic organization of
human cd34, podxl, and endgl genes based on
sequence contigs identified in the human
sequence database (see Materials and Meth-
ods). The location of the coding sequences
for the signal peptide (S, purple), mucin do-
main (S-T-P, blue), cysteine-rich domain
(C-C, green), transmembrane (TM, or-
ange), and cytoplasmic tail (Cyt tail, red) are
indicated. Numbers indicate exon size in
base pairs. The human cd34 gene spans
 25 kbp with a first intron of 11 kbp. The
human podxl gene was found to span  60
kbp with a first intron of 45 kbp. The hu-
man endgl gene spans  23 kbp with a first
intron of 13 kbp. The 3  introns of all three
genes are relatively small; the last four exons
in each case are separated by  3 kbp.
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Abbreviations used in this paper:
 
 AF, amniotic fluid; AJ, adherens junction;
CD2AP, CD2-associated protein; EC, endothelial cell; ES, embryonic
stem; FP, foot process; GBM, glomerular basement membrane; GLEPP,
glomerular epithelial protein; HEV, high endothelial venule; HPRT, hy-
poxanthine-guanine phosphoribosyl transferase; JC, junctional complex;
KO, knockout; MP, major process; NPHS, congenital nephrotic syn-
drome; PECAM, platelet endothelial cell adhesion molecule; SD, slit dia-
phragm; TEM, transmission electron microscopy; TJ, tight junction. 
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the capillary endothelium and then through the GBM. In
the final stage of ultrafiltrate production the filtrate passes
through the SDs between the interdigitating FPs. On ma-
ture podocytes, podocalyxin is a major component of the
apical cell surface where it has been proposed to help main-
tain the spacing between the interdigitating FPs by charge
repulsion (15). The proper function of podocytes as filters
is critically dependent on the anionic nature of the glycoca-
lyx covering the podocytes (17–19). In the 1970s it was
shown that neutralization of this charged glycocalyx by in-
fusion of polycations, or by treatment with glycosidases to
remove negatively charged carbohydrates, results in a rapid
remodelling of the podocyte cytoskeleton with “efface-
ment” or loss of the fine, interdigitating FP structure and
SDs. This, in turn, resulted in nephrosis and massive pro-
teinuria (17–19). With the later discovery that podocalyxin
is the most abundant heavily charged sialomucin expressed
by podocytes, it was speculated that alterations in podoca-
lyxin could be the principal cause of these experimentally
induced nephrotic syndromes (1, 2).
Although mutations in the podocalyxin gene have not
yet been linked to nephrotic syndrome and renal failure,
several other human and murine gene mutations of
podocyte proteins have been identified. These include mu-
tations in nephrin/congenital nephrotic syndrome (NPHS)
gene 1, podocin/NPHS gene 2, 
 
 
 
-actinin-4, CD2-associ-
ated protein (CD2AP), and 
 
 
 
3
 
 
 
1
 
 integrin (20–24). Al-
though the precise function of the proteins encoded by
several of these genes is uncertain they have one common
denominator: their mutation leads to the disruption of nor-
mal podocyte architecture (25–27).
To determine whether podocalyxin plays an essential
role in renal, vascular, and hematopoietic function we have
disrupted the podocalyxin-encoding gene in mice (
 
podxl
 
 
 
/
 
 
 
).
All 
 
podxl
 
 
 
/
 
 
 
 mice die within the first 24 h of postnatal life
from profound defects in kidney and/or gut formation
(herniation or omphalocele). Surprisingly, the loss of
podocalyxin expression did not result in the massive pro-
teinuria characteristic of leaky podocyte filtration in human
nephrotic syndromes. Instead, newborn 
 
podxl
 
 
 
/
 
 
 
 mice
were anuric (no measurable urine in the bladder) and failed
to form FPs and SDs. Our data suggest that podocalyxin is
indispensable for normal murine development and that its
mutation could play a role in podocyte-related renal failure
and in omphalocele (see Discussion).
 
Materials and Methods
 
Genomic Structure and Peptide Motif Analyses.
 
The 8 exons of
 
cd34
 
, 
 
podxl
 
, and 
 
endgl
 
 genes were found by sequence analysis and
database searches. Human 
 
cd34
 
 cDNA (GenBank/EMBL/DDBJ
accession no. M81104) was used to identify the human genomic
locus on clone 8L2 of chromosome 1q32.2-q32.3 (GenBank/
EMBL/DDBJ accession no. AL035091). Human 
 
podxl
 
 cDNA
(GenBank/EMBL/DDBJ accession no. NM005397) was
aligned with the working draft sequence of human chromosome
7 clone RP11-180C16 (GenBank/EMBL/DDBJ accession no.
AC008264), and human 
 
endgl
 
 cDNA (GenBank/EMBL/DDBJ
 
accession no. AF219137) was aligned against the working draft
sequence of human chromosome 15 clone RP11-221C9 (Gen-
Bank/EMBL/DDBJ accession no. AC023593). For structural
predictions of CD34, podocalyxin, and endoglycan, potential
 
O
 
-linked glycosylation sites were predicted using the
www.cbs.dtu.dk/services/NetOGlyc server, and potential phos-
phorylation sites were predicted using subsequence analysis of
protein patterns in MacVector (Oxford Molecular).
 
Targeted Disruption of the Podocalyxin (podxl) Gene.
 
A partial
mouse podocalyxin cDNA clone (534 bp) was produced by re-
verse transcription PCR of mouse kidney RNA using primers to
the 3
 
 
 
-coding sequence of chicken podocalyxin: 5
 
 
 
-GAATTCG-
GCTTCTCGTGGAACTGCTGTGTCACT-3
 
 
 
 and 5
 
 
 
-GAAT-
TCGGCTTCTCCTCATCTAGGTCATCCTTGG-3
 
 
 
. This
probe was used to screen a 129/SvJ phage library in 
 
 
 
FIXII
(Stratagene), and 3 independent mouse 
 
podxl
 
 genomic clones
were identified and purified. A mutant allele of the 
 
podxl
 
 genomic
locus was generated by inserting a neomycin resistance cassette in
the antisense orientation between the XbaI site in exon 5 and an
engineered XhoI site in exon 8 of the m-
 
podxl
 
 gene, thereby de-
leting the majority of exons 5, 6, 7, and 8. The 5.5-kb XbaI frag-
ment containing part of the 5th exon was subcloned into the
XbaI site of the pPNT vector (28) to create the 5
 
 
 
 arm of homol-
ogy in the knockout (KO) vector (29, 30). The 3
 
 
 
 arm of homol-
ogy was created by PCR of an 892-bp fragment from the 3
 
 
 
region of the MEP21 coding sequence using primers 5
 
 
 
-
GCGGCCGCTTACTAGGCATGGTTTTATG-3
 
 
 
 and 5
 
 
 
-
CTCGAGACACCTCTGATCTGTCTGCTGGTC-3
 
 
 
, and
this was cloned into the NotI and XhoI sites of pPNT. The re-
sulting vector was electroporated into E14 embryonic stem (ES)
cells and these were selected for resistance to G418 and against
sensitivity to ganciclovir. Of 672 resistant ES cell clones, 384
were screened by Southern blot analysis for presence of a 5-kb
HindIII fragment using the strategy depicted in Fig. 2. Blastocyst
injection of these ES cells and production of germline transmit-
ting chimeras was performed by RCC Ltd., using standard proto-
cols. Genomic DNA from mouse tail cuts or tissue samples was
isolated using the DNAeasy Tissue Kit (QIAGEN). Genotypes
were determined by PCR using wild-type and KO specific prim-
ers (5
 
 
 
-AGTGAGAGACACATTGGGTAACT-3
 
  
 
wild-type al-
lele specific, 5
 
 
 
-TATCGCCTTCTTGACGAGTTCTT-3
 
  
 
KO
allele specific, and 5
 
 
 
-GAGGATTTGTGCACTCTACAT-
GTG-3
 
 
 
 common primer; GIBCO BRL). The wild-type allele re-
solves as a 760-bp band, while the KO allele resolves as a 550-bp band.
 
Nucleic Acid Analyses.
 
All hybridization probes were labeled
with [
 
32
 
P]dCTP by random hexamer priming as described by
Feinberg and Vogelstein (31). For Southern blot analyses, ES cell
clones were grown in 48-well plates. Cells were lysed and ge-
nomic DNA was ethanol precipitated and digested with HindIII
in the plates using standard protocols (32). DNA samples (
 
 
 
40 
 
 
 
g
per sample) were resolved on 0.7% agarose gels, denatured with
NaOH, and transferred to nylon membranes. Membranes were
hybridized with radiolabeled probes corresponding to the 2,200-
bp ApaI fragment of the podocalyxin 3
 
  
 
untranslated region (see
Fig. 2). Hybridization of radiolabeled probes and removal of un-
bound probe was performed in NaHPO
 
4
 
/SDS buffer as described
by Church and Gilbert (33). In this assay, the wild-type 
 
podxl
 
 lo-
cus resolves as a 4-kb HindIII fragment while the homologously
recombined locus resolves as a diagnostic 5-kb fragment.
For Northern blot analysis, total RNA was prepared by lysis
and fractionation in guanidinium/acetate/phenol/chloroform as
described by Chomczynski and Sacchi (34). Approximately 10
 
 
 
g of each RNA was resolved on a 1% agarose-formaldehyde gel 
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and blotted onto nylon membranes (GeneScreen; Dupont). [
 
32
 
P]-
labeled probes were generated from the 490-bp SmaI-HindIII
fragment encoding the mucin domain of the mouse podocalyxin
cDNA or from a 1,000-bp PstI fragment of the glyceraldehyde-
3-phosphate dehydrogenase cDNA as a control for RNA loading
(35).
 
Histological Analyses and Immunohistochemistry.
 
Immunoperox-
idase staining of snap frozen embryo tissues was performed using
anti-PCLP-1 antibody (7), anti-CD34-biotin (BD PharMingen),
and anti-CD31 (platelet endothelial cell adhesion molecule [PE-
CAM]-1; BD PharMingen), followed by Vector Elite developing
reagents (Vector Laboratories) and methyl green counterstain, as
described previously (5). For paraffin sections, embryonic day 19
kidneys were fixed in 10% formalin, embedded in paraffin, and
sectioned. After deparafinization and hydration the tissue sections
were treated with target unmasking fluid (Signet Labs) for 16 h at
90
 
 
 
C (34) and stained with monoclonal antibodies to glomerular
epithelial protein (GLEPP)1, nephrin, or control rat IgG. Anti-
body binding was revealed by staining with biotinylated goat
anti–rat antibodies, followed by streptavidin-peroxidase, and
3,3
 
 
 
-diaminobenzidine–developing reagent using ABC reagents
and protocols from Vector Laboratories. Sections were counter-
stained with periodic acid-Schiff’s reagent using standard proto-
cols (3). Immunofluorescence staining was performed essentially
as described previously (36). Cryostat sections of mouse E19 kid-
neys were fixed in acetone and incubated with blocking solution
(10% goat or donkey serum in PBS). Primary antibodies used
were chicken anti–mouse GLEPP1 (courtesy of Dr. Roger Wig-
gins, University of Michigan, Ann Arbor, MI); rabbit anti–mouse
nephrin (courtesy of Dr. Lawrence Holzman, University of
Michigan); rabbit anti–mouse collagen 
 
 
 
4(IV) and laminin 
 
 
 
5
(courtesy of Dr. Jeff Miner, Washington University School of
Medicine, St. Louis, MO); mouse monoclonal anti-synaptopodin
(courtesy of Peter Mundel, Albert Einstein College of Medicine,
Bronx, NY); rabbit anti–human Wilm’s tumor protein 1 (Santa
Cruz Biotechnology, Inc.); rat anti–mouse PECAM-1 (BD
PharMingen); and rat anti–mouse laminin, laminin 
 
 
 
1 and 
 
 
 
2
(Chemicon International). For collagen 
 
 
 
4(IV) staining, sections
were pretreated with 6 M urea, 0.1 M glycine for 1 h at 4
 
 
 
C (37).
Secondary antibodies were FITC-conjugated goat anti–rat
(Southern Biotechnology Associates, Inc.), Cy3-conjugated goat
anti–rabbit (Jackson ImmunoResearch Laboratories), FITC-con-
jugated goat anti–mouse (Cappel), and FITC-conjugated donkey
anti–chicken (Lampire Biological Laboratories). All incubations
were carried out in blocking solution. A Nikon Diaphot micro-
scope and a Hamamatsu digital camera were used for acquisition
of immunofluorescence images.
 
Transmission Electron Micrographs.
 
For transmission electron
micrographs (TEMs), newborn kidneys were fixed in cold glutar-
aldehyde/cacodylate buffer. After plastic embedding, one micron
sections were stained with toluidine blue. Selected samples con-
taining glomeruli were thinly sectioned, stained with uranyl ace-
tate, and examined by TEM as described previously (38). The
most mature glomeruli on the sections with open capillary loops
and urinary spaces were examined.
 
Flow Cytometric Analysis.
 
For single color, indirect immuno-
fluorescence analysis, 10
 
6
 
 cells from fetal liver, spleen, or bone
marrow were preincubated with Fc block (anti-mCD16/32.
clone 2.4G2; reference 39) in PBS containing 10% FCS and
0.05% azide. These cells were then stained with either biotin-,
FITC-, or phycoerythrin-conjugated monoclonal antibodies to
CD34 (40), Sca-1 (41), c-kit (42), CD41, Mac1 (43), B220 (44),
CD3 (45), CD4 (46), CD8 (47), or with unlabeled antibodies to
 
Ter119 (48), Gr-1 (49), or PCLP-1 (7) followed by goat anti–rat-
FITC-coupled or biotin-coupled secondary antibodies (BD
PharMingen) as described previously (50). All flow cytometric
analyses were performed using a FACScan™ (Becton Dickinson).
 
Blood, Urine, and Amniotic Fluid Analysis.
 
Newborn mice
were left for 30 min under a heating lamp and then killed by de-
capitation. Blood was collected from the aorta in 50-
 
 
 
l heparin-
ized capillary tubes, and urine was collected in 5-
 
 
 
l capillary
tubes after gentle massage of the bladder. The volume of urine
produced from each mouse was measured and a 2-
 
 
 
l sample was
analyzed for protein content by 10% SDS-PAGE under nonre-
ducing conditions. After electrophoresis, proteins were visualized
by silver staining. Blood samples were clotted and serum was an-
alyzed for their creatinine/urea content using a modified creati-
nine kit (Sigma-Aldrich). Amniotic fluid was collected at 15 d af-
ter coitum and 1 
 
 
 
l of unconcentrated amniotic fluid was
analyzed by 10% SDS-PAGE. As an indirect measure of blood
pressure, day 18 embryos were rapidly dissected and placed in 1
ml of PBS with 1 mM EDTA. The umbilical cord was severed
and embryonic blood was allowed to flow freely for 60 s. The
cord was then clamped, the embryo and placenta were removed,
and the number of RBCs released into the PBS was counted.
 
Results
 
Generation of Podocalyxin-Deficient Mice.
 
To address the
role of podocalyxin in kidney, vascular and hematopoietic
development we generated podocalyxin-deficient mice by
homologous recombination (
 
podxl
 
 
 
/
 
 
 
, Figs. 1 and 2; refer-
ence 28). The 
 
podxl
 
 recombination vector was designed to
delete the majority of the coding sequence for exons 5, 6,
7, and 8, and replace them with the neomycin-resistance
gene in the antisense orientation (Fig. 2 A). These exons
encode 55 amino acids in the extracellular/juxtamembrane
region, the transmembrane region, and the entire cytoplas-
mic tail of podocalyxin and represent the most highly con-
served domains across species (5, 7, 8). The vector was
transfected into E14 ES cells and 384 G418 and ganciclo-
vir-resistant clones were screened for homologous recom-
bination by Southern blot analysis (Fig. 2 B). 16 clones
were identified with the appropriate recombination and
four were injected into blastocysts. Of the four ES cell
clones, one gave 
 
 
 
90% chimerism in six of the resulting
offspring and all of these mice transmitted the targeted allele
to their progeny, as determined by PCR analysis (Fig. 2 B).
These were backcrossed for more than five generations
onto both Balb/c and C57BL/6 backgrounds. Sibling
crosses to generate wild-type (
 
podxl
 
 
 
/
 
 
 
), heterozygous
(
 
podxl
 
 
 
/
 
 
 
), and KO mice (
 
podxl
 
 
 
/
 
 
 
) consistently yielded
offspring of similar phenotype in both genetic backgrounds.
To confirm that podocalyxin expression had been ab-
lated in 
 
podxl
 
 
 
/  mice, Northern blot analysis was per-
formed with RNA isolated from 16-d fetal lungs of
podxl / , podxl / , and podxl /  embryos, using the 5  re-
gion encoding the podocalyxin extracellular domain (lying
outside the region of recombination) as a probe (Fig. 2 C).
This analysis revealed the presence of the expected 5-kb
podocalyxin transcript in wild-type embryos, reduced ex-
pression in heterozygote, and a complete lack of hybridiz-17 Doyonnas et al.
ing transcripts in podxl /  embryos suggesting a loss of ex-
pression from the targeted allele. This was confirmed at the
protein level by cell surface immunofluorescence analysis of
15-d fetal liver cells using a monoclonal antibody to mouse
podocalyxin (Fig. 2 D). Hematopoietic cells from podxl / 
and podxl /  mice expressed high levels of podocalyxin on
their surface, while podxl /  showed no reactivity. From
these analyses we conclude that the engineered rearrange-
ment in the podocalyxin locus has resulted in a complete
loss of podocalyxin expression in podxl /  mice.
Perinatal Lethality, Omphalocele, and Edema in podxl / 
Mice. PCR and Southern blot analyses of 6-wk-old
progeny from heterozygous crosses between podxl / 
mice revealed the complete absence of any podxl /  off-
spring suggesting embryonic or perinatal lethality in mice
lacking podocalyxin. To more accurately pinpoint the
time of disappearance, embryos were harvested at various
stages of development and genotyped by PCR. Although
we observed the expected Mendelian frequency of
podxl / ,  podxl / , and podxl /  offspring throughout
embryonic development, all podxl /  mice died within
the first 24 h of postpartum life (Table I). No statistically
significant differences were observed in the birth weight
of  podxl /  newborns and their podxl /  littermates.
Likewise, no significant differences were noted in the or-
gan weight or macroscopic appearance of the lungs, liver,
heart, gut, and kidneys of the majority of the podxl / 
Figure 2. Generation of podocalyxin-null mutation
in mice. (A) Scheme showing structure of mouse
podocalyxin genomic locus, targeting construct, and
the predicted homologous recombination event. The
targeted disruption results in the deletion of the major-
ity of exons 5, 6, 7, and 8 encoding the 55 amino acids
of the juxtamembrane (“stalk”) domain, the transmem-
brane region (TM), and the cytoplasmic tail (Cyt).
These were replaced with the neomycin resistance cas-
sette (NeoR) in the antisense orientation. Southern blot
probe, restriction sites, and predicted sizes of targeted
and wild-type alleles (HindIII digest) are indicated. (B)
Southern blot and PCR analysis of podocalyxin gene
in targeted ES cell clones and chimeric mice. ES lane
shows a Southern blot of a mutant ES cell clone used
to generate podxl /  mice. The indicated 2.2-kbp ApaI
fragment was used as probe. 4-kbp wild-type (WT)
and 5-kb mutant (KO) alleles are indicated. Genomic
DNA from wild-type ( / ), heterozygous ( / ),
and homozygous KO mice ( / ) were analyzed by
PCR using allele-specific primers (see Materials and
Methods). Molecular weight markers (MW) are indi-
cated in kbp. (C) Northern blot analysis of 16-d em-
bryo lung RNA from wild-type (WT), podxl /  (HT),
and podxl /  (KO) mice. 10  g of total RNA per lane
was hybridized with probes specific to the mucin do-
main of podocalyxin or glyceraldehyde-3-phosphate
dehydrogenase as a control. (D) Analysis of podoca-
lyxin expression by 15-d fetal liver cells. Single cell sus-
pensions from wild-type (WT) and podxl /  (KO)
mice were stained with anti–PCLP-1 antibody fol-
lowed by FITC-conjugated goat anti–rat antibodies
before flow cytometry analysis. Fetal liver cells were
gated on forward and side scatter to focus on the
MEP21 expressing subpopulation of fetal liver.
Table I. Frequency of podxl / , podxl / , and podxl /  
Embryos during Development
Number of animals/genotype  
Age of embryos
(post coitum)  /   /   / 
Frequency of
 /  mice
%
15 d 19 28 17 26
16 d 5 21 10 27
17 d 8 15 10 30
18 d 35 71 30 22
19 d 6 10 8 33
Age of newborn
(post partum) 
1 d 52 100 0 0
Embryos from timed matings were genotyped on embryonic day 15, 16,
17, 18, 19, or 1 d post partum. Far right column shows the observed
percentage of podxl /  mice (the predicted Mendelian percentage is 25%).
mice (although two notable defects were observed in a
subset of the podxl /  mice, see below). Perinatal lethality
persisted when podxl /  mice were delivered by Caesar-
ean section and placed with foster mothers. Thus, the data18 Podocalyxin Knockout Leads to Kidney Failure, Omphalocele, and Lethality
suggest that the loss of podocalyxin results in perinatal
lethality due to defects intrinsic to podxl /  mice.
Although the majority of newborn podxl /  mice dis-
played no overt defects, two significant anomalies were
observed in a subset of these mice: edema and omphalo-
cele. Careful analysis of the embryos obtained by Caesar-
ean section shows that  25% of the podxl /  embryos (3/
12 at embryonic day 18 and 4/15 at embryonic day 15)
exhibited mild to severe edema. This usually appeared as
subdermal swelling as early as 15 d after coitum (Fig. 3)
and a mildly turgid trunk and appendages at day 18 (data
not shown). More strikingly,  30% of all podxl /  mice
were born with an “omphalocele” or herniation of the
gut into the umbilical cord (Fig. 4, A and B). No direct
correlation was observed between embryonic edema and
omphalocele;  podxl /  embryos at day 18 were equally
likely to have one, the other, or both defects. However,
neither defect was ever observed in any day 18 podxl / 
or  podxl / mice suggesting a strict correlation with
podocalyxin loss.
Omphalocele is a normal physiologic process that occurs
transiently during the embryogenesis of all mammals. It is
known that at midgestation, the rapidly enlarging visceral
organs soon exceed the limiting space of the peritoneal
cavity. As a result, the developing gut herniates into the
umbilical space (this begins at embryonic day 12 in mice;
reference 51). Normally this “physiologic omphalocele” is
resolved by the subsequent expansion of the peritoneal cav-
ity and retraction of the gut from the umbilical cord. In
mice, this retraction is completed by the 16th day of embry-
onic development (51). To assess the ontogeny of gut her-
niation in podocalyxin-deficient mice, timed matings were
performed and podxl / , podxl / , and podxl /  embryos
were evaluated at daily intervals for the presence or absence
of omphalocele (Fig. 4 D). As expected, wild-type embryos
showed a complete resolution of the physiologic omphalo-
Figure 3. Edema. (A) Light mi-
crograph of day 15 podxl /  ( / )
embryo and one of a podxl /  ( / )
embryo with edema. (B) Close-up
color micrograph of day 15 podxl / 
embryo with edema. Arrows indicate
the dorsal region of embryonic trunk
where subdermal swelling occurs in
 /  embryos.19 Doyonnas et al.
cele by embryonic days 15 or 16. In contrast, virtually all
podxl /  embryos (13/14) displayed omphalocele up to
embryonic day 17. Subsequently (and before birth), 70% of
these mice resolved the omphalocele resulting in a 30% in-
cidence in newborns. podxl /  mice displayed an interme-
diate phenotype (8/35 displayed omphalocele on day 17),
suggesting partial impairment due to loss of one podxl allele
(Fig. 4 C). This phenotype may be linked to the prominent
expression of podocalyxin on mesothelial cells lining the
serous body cavities (Fig. 4 D). Thus, although omphalo-
cele is only observed in a subset of neonates, the data sug-
gest that all podocalyxin-deficient mice (and a subset of
heterozygotes) present with some degree of abnormal
omphalocele during development.
Podocalyxin Deficiency Leads to Symptoms Consistent with
Neonatal Anuric Renal Failure. The observation that only a
subset of newborn podxl /  have overt defects, and yet
100% of these mice die perinatally prompted us to perform
more detailed analyses of organ function in these mice.
Since podocalyxin is most prominently expressed in kid-
neys, we aspirated bladder contents to analyzed urine from
newborns. Strikingly, 100% of the podxl /  newborns (12/
12) exhibited a lack of urine in the bladder suggestive of se-
verely impaired kidney function (Fig. 5 A). Consistent with
anuria (and not proteinuria) SDS-PAGE analysis of blood
serum and amniotic fluid proteins showed no significant
differences in protein constituents from wild-type and KO
mice. Anuria is one of several clinical features of acute renal
failure and can lead to intravascular volume expansion and
hypertension. Other symptoms include increased blood
pressure and elevated levels of serum creatinine and urea.
Although direct measurement of blood pressure was not
possible in newborn mice, we attempted to measure this
indirectly by assessing cardiac output. Day 18 embryos
were collected by Caesarean section, the umbilical cord of
each embryo was severed and the RBCs were collected in a
solution of PBS/EDTA for 60 s. These were then counted
as a rough measure of cardiac output/blood pressure (Fig. 5
B). While no significant differences were observed between
podxl /  and podxl /  embryos, podxl /  embryos exhib-
ited an  15-fold increase in released RBCs over the 60-s
interval (most were released within the first 15 s). Consis-
tent with this observation, podxl /  embryos frequently ap-
peared pale when the umbilical cords were severed in solu-
tions that prevented clotting. This did not reflect an
inability to clot as no differences in pallor were observed
when the umbilical cords were severed in the absence of
aqueous anti-coagulants, and we have not observed any dif-
ferences in the frequency or function of platelets in podxl / 
mice (see below). An increase in blood pressure may offer
an explanation for the edema observed in podxl /  em-
bryos: excessive pressure could drive fluid into the extravas-
cular spaces. Although there were no significant differences
in serum creatinine/urea levels between wild-type and
podxl-deficient mice, it is likely that such changes would
only appear after 1 or 2 d of life postpartum (during em-
bryogenesis these would be removed maternally). New-
born mice with anuric renal failure have been described to
consistently die in the first day of life (52–55), and thus it is
likely that podxl /  mice die due to kidney failure.
Podocalyxin Is Required for Normal Formation of Podocyte
FPs in Developing Kidneys. To more clearly define the de-
fects in podxl /  kidneys, we examined glomerular devel-
opment in wild-type and podxl /  animals. Periodic acid-
Schiff staining of sections from newborn kidney revealed
the presence of glomeruli in all stages of development in
both podxl /  and podxl /  mice but with subtle differ-
ences. In some of the mature juxtamedullary glomeruli of
the podxl /  kidneys lucent areas (vacuoles) were observed
which were distinct from the normal capillary loops (Fig. 6
A, and data not shown). During embryogenesis the onset of
podocalyxin expression correlates with early podocyte dif-
ferentiation from mesenchymal progenitors at the “S-
shaped body” stage of glomerular development (15). To
Figure 4. Omphalocele. (A) Light micro-
graph of day 18 podxl /  and podxl /  em-
bryos. Arrow indicates umbilical cord and
omphalocele. (B) Close-up color micro-
graph of omphalocele in podxl /  newborn.
(C) Ontogeny of omphalocele in wt,
podxl / , and podxl /  mice. Blue, red, and
green symbols indicate wt, podxl / , and
podxl /  mice, respectively. Each data point
represents the percentage of between 5 and
35 animals analyzed. (D) Analysis of
podocalyxin expression in physiologic
omphalocele of wild-type mice. Sections
from 16-d embryo gut were immunostained
for podocalyxin (brown stain) and counter-
stained with methyl green. Podocalyxin is
expressed by mesothelial cells lining the
outer aspect of the gut (red arrows) and by
capillary ECs in the villi (black arrows).20 Podocalyxin Knockout Leads to Kidney Failure, Omphalocele, and Lethality
determine whether podocalyxin loss results in a failure of
podocyte maturation, kidneys from newborn mice were
sectioned and analyzed by immunohistochemistry for ex-
pression of two later markers of podocyte differentiation:
GLEPP1, a transmembrane tyrosine phosphatase of kidney
podocytes (56) and nephrin, a transmembrane protein asso-
ciated with podocyte SDs that plays a critical role in
podocyte function (20, 57). Wild-type, podxl / , and
podxl /  kidneys all displayed the expected GLEPP1 and
nephrin staining on podocytes in the glomeruli (Fig. 6 A,
and data not shown), indicating that podocyte differentia-
tion and expression of these maturation markers is not im-
paired by the lack of podocalyxin. However, the morphol-
ogy of the podocytes was clearly altered in podxl /  mice:
consistent with the periodic acid-Schiff stains, distinct lu-
cent areas suggestive of void spaces and vacuoles were ob-
served within the podocytes of podxl /  mice (Figs. 6 A
and 7 A). To ensure that this was due to alterations intrinsic
to the podocytes and not to alterations in protein expres-
sion by the vascular ECs or GBMs, dual-label immunoflu-
orescence analysis was performed with vascular/GBM
markers (PECAM-1, collagen  4(IV), and laminins  5,  1,
and  2) and podocyte markers (Wilm’s tumor gene prod-
uct [58], GLEPP1 [56], nephrin [20, 57], and synaptopodin
[59]). We found no evidence of loss of expression of any
GBM proteins in wild-type and podxl /  kidneys (Fig. 6,
and data not shown). The mature glomeruli of the new-
born podxl /  and podxl /  mice showed similar expression
levels of collagen and laminin isoforms in mature GBM
(Fig. 6, B and C, and data not shown). Normally, podocyte
FP and GBM proteins appear to have an overlapping stain-
ing pattern at the light microscopy level. This reflects the
fact that the thin FPs of podocytes are in very close prox-
imity to the GBM rather than true “colocalization”. Inter-
estingly we noted a consistent reduction in the degree of
“side-by-side” podocyte and GBM-marker staining in
podxl /  kidneys. For example, while dual immunofluores-
cence-labeling showed the normal close proximity of the
podocyte markers nephrin and GLEPP1 with the GBM in
wild-type mice (note the red/green proximity in Fig. 6, B
and C), there was a marked decrease in the degree of over-
lap in the podxl /  glomeruli. This indicates either a
greater-than-normal distance between the podocyte apical
membranes and the GBM (cell thickening) or incomplete
coverage of the basement membranes by podocyte FPs.
To assess the defects in the podxl /  podocytes more
precisely, kidneys were analyzed by TEM. TEM of the
most mature glomeruli from newborn podxl /   and
podxl /  mouse kidneys showed well-developed MPs and
FPs (Fig. 7 A, and schematic in Fig. 8). By contrast, in the
podxl /  kidneys, MPs were greatly reduced in number
and the FPs and SDs were completely absent. Interest-
ingly, numerous junctional complexes (JCs) (tight junc-
tions [TJs] and AJs) were observed between adjacent
podocytes (Fig. 7, A and B) consistent with impermeable
cell–cell junctions. Moreover, the podocytes in podxl / 
mice completely engulf the vasculature with their cell
bodies and the urinary spaces were markedly reduced.
Consistent with light microscopic observations (see above)
large intracellular vacuoles were present in the podocytes
of podxl /  mice (Figs. 6 A and 7 A). On the endothelial
side of the GBM the ECs had some, but fewer, fenestrae
and in general the EC layer appeared thicker than in wild-
type mice (Figs. 7 and 8). These ultrastructural findings are
consistent with the lack of urine production in podxl / 
mice and this is most likely cause of death in podocalyxin-
deficient mice (Fig. 8).
Vascular Development. Since podocalyxin is also ex-
pressed on vascular ECs we next examined the distribution
of these cells in whole-mount sections of 16-d podxl / 
and podxl /  embryos by immunocytochemistry. Stains of
embryos with CD31 (PECAM-1) and CD34 antibodies
show no detectable differences in the expression pattern of
Figure 5. Urine production and cardiac output. (A) Urine collected
from the bladders of 18-d-old embryos after Caesarian section. Represen-
tative data from one of two similar experiments. White bars, wild-type
embryos; black boxes, podxl /  embryos; gray boxes, podxl /  embryos.
(B) 60-s cardiac output from 18-d-old embryos as determined by RBCs
released from umbilical cord. White bars, wild-type embryos; black
boxes, podxl /  embryos; gray boxes, podxl / embryos.21 Doyonnas et al.
these molecules between podxl /  and podxl /  in brain,
gut, kidney, or lung. However, a consistent increase in the
expression levels of CD34 was detected particularly in kid-
ney and lung (Fig. 9 A, and data not shown). Quantifica-
tion of CD34 mRNA from kidney revealed a three to
fourfold increase in CD34 transcripts in podxl /  mice ver-
sus podxl /  mice (Fig. 9 B), while the frequency of control
hypoxanthine-guanine phosphoribosyl transferase (HPRT)
mRNAs were found to be identical in null and wild-type
mice. This result suggests that a loss of podocalyxin expres-
sion by the vasculature may result in a compensatory in-
crease in the expression of the related sialomucin, CD34.
Consistent with normal vasculature in areas of CD34/
podocalyxin coexpression, TEM analyses of newborn lungs
from podocalyxin-deficient mice revealed no overt defects
in formation of pulmonary capillaries or bronchial-associ-
ated epithelia (data not shown). Unfortunately, the third
member of the CD34 family, endoglycan, is expressed by a
variety of nonvascular cell types making the assessment of
its upregulated expression on vessels problematic (unpub-
lished data, and reference 13). We conclude that the vascu-
lar development in podxl /  mice is essentially normal, pos-
sibly due to the upregulated expression of the related
molecule, CD34.
Hematopoietic Development is Normal in podxl /  Em-
bryos. Because our own previous studies in the chick (5,
50) and recent studies in the mouse (7) have shown that
podocalyxin is a marker of the earliest hematopoietic pro-
Figure 6. Histological analysis of podxl /  kid-
neys. (A) Immunohistological analysis of expression
of the podocyte-specific tyrosine phosphatase,
GLEPP1 in podxl / , podxl / , and podxl /  kid-
neys. The capillary loops of the podxl /  and
podxl /  glomeruli are shown in black arrows.
podxl /  glomeruli had similar capillary loops but
also had numerous lucent vacuoles surrounded by
GLEPP1 staining (red arrows). Scale bars, 50  m.
(B) Dual-label indirect immunofluorescence of
newborn mouse kidney from podxl /  and podxl / 
(top and bottom, respectively) with antibodies to
GLEPP1 (donkey anti-chicken FITC labeled sec-
ondary antibody), and collagen  4 (type IV) (goat
anti–rabbit Cy3-labeled secondary antibody). Stain-
ing for the apical membrane podocyte marker
GLEPP1 and the basement membrane protein col-
lagen  4 (type IV) is seen in mature glomeruli in
podxl /  and podxl /  mice. Superimposition of
these images shows areas of strong overlap (orange)
in the podxl /  mice. In the podxl /  mice the area
of overlap (orange) is diminished representing a
greater distance in the localization of the apical
membrane marker (GLEPP1) from the basement
membrane. (C) Dual-label indirect immunofluo-
rescence of newborn mouse kidney from podxl / 
and podxl /  (top and bottom, respectively) with
antibodies to the basement membrane protein
laminin   2 (FITC-conjugated goat anti–rat) and
podocyte slit diaphragm protein nephrin (anti–rab-
bit Cy3-labeled secondary antibody). Strong stain-
ing is seen for both markers in podxl /  and
podxl /  mice. The close proximity of the slit dia-
phragm (nephrin staining) to the basement mem-
brane (laminin  2 staining) can be appreciated in
the superimposed images by the presence of over-
lapping staining (orange) in the podxl /  mice. In
the  podxl /  glomeruli the superimposed images
show diminished overlap (orange staining) of the
expression of nephrin and laminin  2.22 Podocalyxin Knockout Leads to Kidney Failure, Omphalocele, and Lethality
genitors, we performed an extensive analysis of the he-
matopoietic development in wild-type and podocalyxin-
deficient mice. Hematopoietic tissues from podxl / ,
podxl / , and podxl /  embryos were stained with antibod-
ies to CD34, Sca-1, c-kit, Ter119, CD41, Mac1, Gr-1,
B220, CD3, CD4, and CD8 to assess the numbers of he-
matopoietic progenitors and erythroid, megakaryocytic/
platelet, myeloid, granulocytic, and B and T lineage cells,
respectively. We observed no differences in the frequency
or phenotype of any hematopoietic lineages in 15-d fetal
liver, 18-d bone marrow, or 18-d spleen of podxl /  em-
bryos. Likewise, we observed no defects in the formation
or localization of hematopoietic and vascular cells in
podocalyxin-deficient yolk sac, lung, heart, liver, or gut.
Thus, the data suggest that podocalyxin is either dispens-
able for the formation of these cell types, or its loss can be
compensated for by other related molecules.
Discussion
In this study, we have generated mice lacking the sialo-
mucin, podocalyxin. These mice die during the first day
of life with severe kidney abnormalities and a pathology
consistent with neonatal anuric renal failure. While some
of the null mice had edema and/or displayed omphalo-
cele, most appear normal at birth. Thus, despite the ex-
pression of podocalyxin by most vascular endothelia, a
subset of mesothelial cells and hematopoietic stem cells,
the abnormalities in the podxl /  mice were largely con-
fined to the kidney.
Role of Podocalyxin in Glomerular Structure and Function.
In kidneys, the final stage of glomerular filtrate production
occurs when the ultrafiltrate passes through the filtration
slits between neighboring podocyte FPs. The specialized
cell–cell junctions between podocyte FPs forming the slit
diaphragm provides the last barrier for filtrate production
(Fig. 8). The permeability of the glomerular filter is highly
dependent on the filtration slit surface area and the filtra-
tion properties of the slit diaphragm (60, 61). The
podocytes of podxl /  mice do not form FPs or SDs and
instead form impermeable TJs. The absence of SDs and
the reduction of filtration slit area due to the lack of inter-
digitating FPs in the podxl /  mice probably leads to
Figure 7. TEMs of embryonic day 18 kidneys from podxl /  and
podxl /  embryos. (A) podxl /  kidneys have normal podocytes (Pod.)
with typical MPs and FPs that embrace the outer aspect of the capillary
basement membrane. RBCs can be seen in the lumen of the endothelial
vessels. podxl /  show a complete loss of SDs and FPs. JCs are present be-
tween all of the podxl /  podocytes. Podocytes in podxl /  mice also dis-
play numerous vacuoles (Vac.) and overall the glomerular capillaries had a
thicker EC layer (EC). Scale bars, 2  m. (B) Higher magnification reveals
that the SDs and FPs indicated by arrows in the podxl /  and podxl / 
mice are completely lost in podxl /  glomeruli. JCs including TJs and AJs
are present between podxl /  podocytes. The endothelial fenestrae (F)
within the ECs can be found in wild-type controls but the fenestrae re-
duced in the podxl /  glomerular capillaries. Scale bars, 0.2  m.
Figure 8. Schematic representation of the glomerular filter in wild-
type and podocalyxin-deficient mice (adapted from reference 14). For
ease of presentation, the mesangial cells that would normally link the cap-
illary loops (disrupting the layer of podocytes) have been left out of the
diagram. The lack of interdigitating FPs in the podxl /  mice leads to a
lack of filtration slit area. This, along with the decrease in the fenestration
of the glomerular capillaries, is thought to lead to a decrease in the poten-
tial area for filtration and the anuria that occurs in the podxl /  mice.23 Doyonnas et al.
glomerular filters with reduced permeability that result in
anuria at birth.
It has been speculated that the charge of podocalyxin is
required for maintaining the spacing between FPs (15)
since podocalyxin is the major constituent of the glycoca-
lyx at their apical surface. This is supported by the fact that
the inducible, ectopic expression of podocalyxin in Chi-
nese hamster ovary cells and Madin-Darby canine kidney
epithelial cells results in the inhibition of cell aggregation
and in an altered organization of junctional proteins in ad-
herent cell monolayers (62). Moreover, ectopic expression
was shown to inhibit the formation of electrical-resistant
monolayers of epithelial cells, indicating that podocalyxin
can block the formation of TJs. Our data clearly support
and extend this finding; in the absence of podocalyxin, JCs
persist between podocytes and they fail to migrate down
the lateral surface towards the basement membrane where
they are normally modified to form SDs. The failure of the
podocytes in podxl /  mice to form permeable cell–cell
junctions (SDs) is consistent with a role for podocalyxin as
an antiadhesin on the surface of the podocytes and as a po-
tential regulator of cell junctions.
It has been suggested that one way podocalyxin regulates
cell–cell junctions is by interacting with the actin cytoskel-
eton, possibly via the actin-associated protein ezrin. The
COOH-terminal tail of podocalyxin (D-T-H-L) is highly
homologous to that of endoglycan and CD34 (D-T-H/E-L;
Fig. 1 A). All three molecules contain the consensus se-
quence (X-S/T-X-V/I/L) recognized by proteins with
PDZ protein interaction domains (63). PDZ-containing
proteins can act as scaffolds to link transmembrane proteins
in multiprotein complexes that may include the actin cy-
toskeleton (64). Indeed, one of us (unpublished data) re-
cently found that the COOH terminus of podocalyxin in-
teracts with NHERF-2, a PDZ domain-containing protein
that can link transmembrane proteins to the actin cytoskel-
eton via ezrin (65). In light of the present studies we feel it
is likely that this linkage is important in the modification of
JCs in mature podocytes.
The vacuoles observed in the podocytes of podxl / 
mice are similar to the podocyte vacuoles seen in human or
rodent models of renal disease (66–69). These vacuoles can
occur in the setting of minimal change disease or in models
where there is extensive podocyte injury (puromycin ami-
nonucleoside–induced nephrosis). They have been hypoth-
esized to result from the abnormal passage of fluid from the
basolateral to apical surface of the podocyte in situations
where there is extensive FP effacement or disruption of
normal slit diaphrams (70, 71). Considering the lack of per-
meable cell–cell junctions and FPs in the podxl /  mice,
these podocyte vacuoles may result from the lack of a para-
cellular pathway for filtrate production and this “salvage
pathway” may contribute to the bulk of fluid seen in the
urinary space of the podxl /  mice.
Podocalyxin Deficiency: Relation to other Podocyte-specific
Mutations. Several proteins proposed to be involved in
the formation of JCs between podocytes have been iden-
tified recently as crucial regulators of podocyte func-
tion.  These include nephrin/NPHS1, podocin/NPHS2,
CD2AP, P-cadherin,     catenin,  -actinin-4, and ZO-
1  (16, 20–23, 72). All of these proteins are expressed at
the SDs between processes and have been speculated to
participate in the formation of modified AJs (16, 26).
Nephrin and P-cadherin are thought to interact by homo-
typic recognition and to be responsible for maintenance of
the filtration slits (16, 20, 26). CD2AP has been shown to
interact with the intracellular domain of nephrin (23)
whereas     catenins bind the intracellular domain of
P-cadherin. Human mutations in NPHS2 or   actinin 4
result in proteinuria and FP effacement (21, 22). Ablation of
CD2AP and nephrin in mice leads to nephrotic syndrome
with massive proteinuria and effacement of the FPs. A
striking difference between podxl /  mice and mice lacking
nephrin or CD2AP is that the latter mice exhibit massive
proteinuria and are still able to develop podocyte FPs (20,
23) whereas the podxl /  mice lack FPs and produce no
urine. These results support the contention that podoca-
lyxin has a fundamentally distinct function in podocyte cell
Figure 9. CD34 mRNA overexpression in kidney of podxl /  18-d
embryos. (A) CD34 immunostaining of 18-d embryo kidneys. Brown
stain represents CD34 antigen detected by immunoperoxidase stain; green
stain represents methyl green counterstain of nuclei. (B) Relative quantifi-
cation of CD34 and HPRT mRNA in 18-d embryo kidney by Real-
Time reverse transcription PCR (LightCycler™; Roche). Y-axis, relative
level of cDNA product as determined by SYBR Green™ fluorescence;
X-axis, number of PCR cycles; Pink lines, podxl /  mRNA with CD34
primers; purple lines, podxl /  mRNA with CD34 primers; light green
lines, podxl /  mRNA with HPRT primers; dark green lines, podxl / 
mRNA with HPRT primers. One of four representative experiments
with kidney mRNA from two independent mice of each genotype.24 Podocalyxin Knockout Leads to Kidney Failure, Omphalocele, and Lethality
junctions (increased permeability) from nephrin/CD2AP
(increased barrier function).
Aside from the proteins found in JCs, only a small
number of other membrane proteins located at the apical
surfaces of podocytes have been defined. They include
podoplanin, a protein that is also expressed on nonpolar-
ized cells (73), and GLEPP1, a transmembrane protein
tyrosine phosphatase (38). GLEPP1 appears to regulate
podocyte FP structure since deletion of this gene (ptpro)
leads to toe-like podocyte FPs that are shorter and
broader than the FPs of normal mice. Although ptpro / 
mice are viable and develop normally, they have a re-
duced glomerular filtration rate and after partial nephrec-
tomy display a predisposition to hypertension. Thus, al-
though the defects in ptpro /  mice are much milder than
those of podxl /  mice, they also display a reduced glo-
merular filtration rate due to abnormalities in FP forma-
tion.
The fact that podxl /  podocytes express the normal rep-
ertoire of both apical and junctional-complex podocyte
markers suggests that maturation of these cells is relatively
normal and that the observed defects in urine production
are not due to defects in downstream protein expression.
Rather, our results argue that podocalyxin loss leads di-
rectly to structural malformations of FPs. Similar to the
neonatal lethality observed in podxl /  mice, there are sev-
eral other reports of anuric mice that die in the first day of
life (52–55). However, it is noteworthy that most of these
mutations result in much more severe kidney defects
(agenesis) or in pleiotropic defects in other vital organs.
Thus, podocalyxin loss represents the most selective, lethal
anuria described to date.
Role of Podocalyxin in Resolution of Physiologic Omphalo-
cele. In normal mouse development, the gut herniates
into the umbilical space through the umbilical ring begin-
ning at embryonic day 12 and retracts back into the peri-
toneal cavity by the 16th day of embryonic development
(58). This “physiologic omphalocele” is resolved by the
expansion of the peritoneal cavity and retraction of the
gut from the umbilical cord. While only a subset of
podocalyxin-null mice displayed omphalocele at birth, all
null mice showed delay in omphalocele resolution in
utero. Surprisingly, some heterozygotes showed a similar
delay suggesting a dosage effect of this mucin on the reso-
lution of omphalocele. Omphalocele is a relatively com-
mon congenital birth defect in man, affecting  1:6,000
children, but the molecular details of its etiology are
poorly understood. In many cases omphalocele has been
linked to syndromes with abdominal organomegaly or de-
fects in the development of the anterior abdominal wall
leading to failure of umbilical ring closure (74). However,
examination of podxl /  mice revealed no abdominal or-
ganomegaly. Because of the dosage effect and because
podocalyxin is expressed by the mesothelial cells lining
the peritoneal membrane, we speculate that mesothelial
function of this molecule is to provide an antiadhesive
surface and facilitate retraction of the gut through the
umbilical ring (see below).
Function and Redundancy of CD34-related Molecules in De-
velopment. Despite the widespread expression of sialomu-
cins in many tissues their function is still poorly understood
and, until now, ablation of sialomucins have not resulted in
a lethal phenotype. This suggests that most sialomucins are
either dispensable for normal development or that there are
mechanisms that compensate for their loss such as redun-
dancy. The podxl /  mice provide the first example of a
sialomucin that is critically required for the normal devel-
opment and postnatal survival of mice. Since podocalyxin
deficiency causes defects in tissues that selectively express
podocalyxin but not CD34 (gut mesothelial cells and
podocytes), while coexpressing tissues are spared (vascular
endothelia and hematopoietic precursors), it is tempting to
speculate that CD34 and podocalyxin can, indeed, cross-
compensate. Our observation that CD34 expression is up-
regulated in podxl /  mice is consistent with this idea and it
will now be interesting to determine whether podxl / /
cd34 /  double KO mice exhibit hematopoietic and vascu-
lar defects (unpublished data).
Two opposing hypotheses have been proposed for the
functions of the CD34 family of sialomucins: adhesion and
antiadhesion. In favor of the adhesion model both podoca-
lyxin and CD34, when expressed by HEVs, can act as ad-
hesive tethers for activated leukocytes migrating into
lymph nodes (8, 10). Lymphocytes use L-selectin (a C-type
animal lectin) to bind to specific glycoforms of CD34 and
podocalyxin expressed on the surface of HEVs and this is
the initiating step in lymphocyte extravasation from blood
into the lymph nodes. A caveat, however, is that L-selectin
binding to these molecules is glycosylation specific and the
appropriate modifications have usually only been observed
on HEVs. Therefore, it is likely that in most tissues,
podocalyxin and CD34 have alternate functions other than
adhesion. Based on a number of studies, other researchers
have speculated that podocalyxin (and in some circum-
stances CD34; reference 75) can act as an antiadhesion
molecules or molecular “Teflon™” by virtue of its nega-
tively charged mucin domain (1, 2, 15, 62, and see above).
One exciting hypothesis is that, in fact, these molecules
can serve both adhesive and antiadhesive functions. Under
the majority of circumstances, these molecules provide a
barrier to adhesion, increase monolayer permeability, and
aid in modifying JCs. In the special case of the HEVs, how-
ever, these molecules provide dual functions. In the first
step they provide tethers for leukocytes expressing L-selec-
tin binding. Subsequently, however, podocalyxin and
CD34 move to the junctions between ECs where they act
to “spread” the endothelia and facilitate leukocyte transmi-
gration. This is consistent with previous reports showing
movement of CD34 to junctions in response to cell activa-
tion (75). Analysis of mice lacking multiple members of the
CD34 family offers an opportunity to test this model and
should clarify this issue.
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